Targeting a diverse spectrum of cancers.
Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.
Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.
05/24/18 4:00 PM EDT
© Nasdaq. Minimum 15 minutes delayed.
Deciphera Pharmaceuticals Expands Board with the Election of Mr. Steven L. Hoerter as a Director Read More »
Deciphera Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Read More »
Deciphera Pharmaceuticals, Inc. Announces First Quarter 2018 Financial Results Read More »